CoChat

GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit

Mancini, A. D., Poitout, V. · 2015 · Diabetes, Obesity and Metabolism
Cited by 99

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The free fatty acid receptor GPR40 has been proposed as a potential target for type 2 diabetes ( T2D ) pharmacotherapy. This idea has been validated in both preclinical and clinical studies, in which activation of GPR40 was shown to improve glycaemic control by stimulating glucose‐dependent insulin secretion; however, the recent termination of phase III clinical trials using the GPR40 agonist TAK ‐875 (fasiglifam) has raised important questions regarding the long‐term safety and viability of targeting GPR40 and, more specifically, about our understanding of this receptor's basic biology. In the present review, we provide a summary of established and novel concepts related to GPR40 's pharmacobiology and discuss the current status and future outlook for GPR40 ‐based drug development for the treatment of T2D .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12442

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 99

Metadata

Authors
Mancini, A. D., & Poitout, V.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-02-24
Volume
17
Issue
7
Pages
622-629
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1979400849
Cited by
99
References
14
FWCI
14.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.